Phaseline

Targets › PIK3CD

PIK3CD (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform): drug programs, companies and trials

14 programs from 13 companies in 37 trials: 18 Phase 2, 16 Phase 1, 3 Phase 3; Oncology, Immunology, Other; next expected readout Nov 2026.

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, O00329)

Open in Phaseline: the race on PIK3CD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pharming TechnologiesLeniolisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 3APDS; Primary Immunodeficiency Disorders (PIDs); PIDs Linked to PI3KNov 2026
SecuraBioDuvelisib
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 3Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia …Feb 2028
IncyteParsaclisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 2B-Cell MalignanciesNov 2026
National Cancer Institute (NCI)Copanlisib Hydrochloride
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 2Advanced Lymphoma; Follicular Lymphoma; Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm …Dec 2026
Rhizen PharmaceuticalsTenalisib (RP6530)
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 2Triple Negative Breast Cancer (TNBC)Dec 2026
National Cancer Institute (NCI)Umbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Grade 1 Follicular LymphomaJan 2027
City of Hope Medical CenterUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Mantle Cell LymphomaJul 2027
Christian BuskeCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 2Marginal Zone LymphomaDec 2027
Jennifer R. Brown, MD, PhDUmbralisib
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 2Chronic Lymphocytic LeukemiaJan 2028
Kyowa KirinZandelisib (ME-401)
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 2Indolent B-cell Non-Hodgkin's LymphomaMay 2028
Incyte Biosciences Japan GKparsaclisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 1Non Hodgkins LymphomaDec 2026
Brown UniversityCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 1Metastatic Castration-resistant Prostate CancerJan 2027
University of ChicagoUmbralisib (TGR-1202)
PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor
PIK3CD, CSNK1E, ABL1Phase 1CLLDec 2027
Dana-Farber Cancer InstituteCopanlisib
PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor
PIK3CA, PIK3CDPhase 1Diffuse Large B Cell Lymphoma–

Conditions

Chronic Lymphocytic Leukemia (2) APDS (2) Advanced Lymphoma (2) Advanced Malignant Solid Neoplasm (2) Lymphoma (2) Mantle Cell Lymphoma (1) Metastatic Castration-resistant Prostate Cancer (1) Non Hodgkins Lymphoma (1) Primary Immunodeficiency Disorders (PIDs) (1) PIDs Linked to PI3K (1) B-Cell Malignancies (1) Grade 1 Follicular Lymphoma (1)

Modalities

mixed (7), small molecule (7)

Companies

National Cancer Institute (NCI) (2) City of Hope Medical Center (1) Brown University (1) Jennifer R. Brown, MD, PhD (1) Incyte Biosciences Japan GK (1) Pharming Technologies (1) Incyte (1) Christian Buske (1) Kyowa Kirin (1) Rhizen Pharmaceuticals (1) University of Chicago (1) SecuraBio (1) Dana-Farber Cancer Institute (1)

Related targets

CSNK1E (4) ABL1 (4) PIK3CA (4) PIK3CG (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.